Leukotrienes as Mediators in Ischemia-Reperfusion Injury in a Microcirculation Model in the Hamster

H. A. Lehr, A. Guhlmann, D. Nolte, D. Keppler, K. Messmer

*Department of Experimental Surgery, University of Heidelberg, 6900 Heidelberg, Germany; †Division of Tumor Biochemistry, German Cancer Research Center, 6900 Heidelberg, Germany; ‡Institute for Surgical Research, University of Munich, 8000 Munich, Germany

Abstract

Leukotriene (LT)B4 promotes leukocyte chemotaxis and adhesion to the endothelium of postcapillary venules. The cysteinyll leukotrienes, LTC4, LTD4, and LTE4, elicit macromolecular leakage from this vessel segment. Both leukocyte adhesion to the endothelium and macromolecular leakage from postcapillary venules hallmark the microcirculatory failure after ischemia-reperfusion, suggesting a role of leukotrienes as mediators of ischemia-reperfusion injury.

Using the dorsal skinfold chamber model for intravital fluorescence microscopy of the microcirculation in striated muscle in awake hamsters and sequential RP-HPLC and RIA for leukotrienes, we demonstrate in this study that (a) the leukotrienes (LT)B4 and LTD4 elicit leukocyte/endothelium interaction and macromolecular leakage from postcapillary venules, respectively, that (b) leukotrienes accumulate in the tissue after ischemia and reperfusion, and that (c) selective inhibition of leukotriene biosynthesis (by MK-886) prevents both posts ischemic leukotriene accumulation and the microcirculatory changes after ischemia-reperfusion, while blocking of LTD4/E4 receptors (by MK-571) inhibits posts ischemic macromolecular leakage.

These results demonstrate a key role of leukotrienes in ischemia-reperfusion injury in striated muscle in vivo. (J. Clin. Invest. 1991. 87:2036–2041.) Key words: intravital fluorescence microscopy • microcirculation • striated muscle • leukocyte/endothelium interaction • macromolecular leakage

Introduction

Reperfusion injury after focal ischemia to organs and skeletal muscle has been implicated in the development of multi-organ failure and death after primarily successful resuscitation from multiple injury and shock (1). Chemotactic accumulation, activation, and adherence of circulating leukocytes to the endothelium of postcapillary venules hallmark the microcirculatory manifestations of ischemia-reperfusion injury (2–7). Enhanced leukocyte aggregation and altered viscoelastic properties of activated leukocytes favor microvascular obstruction (3, 5). Toxic oxygen radicals and degradation products like hydrolytic enzymes contribute to the full manifestation of ischemia-reperfusion injury (8–11), characterized by the breakdown of capillary perfusion and the loss of endothelial integrity (2, 5, 12).

Leukotrienes, metabolites of arachidonic acid produced in the 5-lipoxygenase pathway, initiate many of the symptoms associated with ischemia-reperfusion injury. The cysteinyll leukotrienes (LT), LTC4, LTD4, and LTE4, affect the tonus of the arterioles and the permeability of postcapillary venules, thereby causing endothelial contraction and macromolecular leakage (13–16). The dihydroxylated LTB4, one of the most powerful chemotactic substances known, has been implicated in the process of leukocyte accumulation, adhesion to the microvascular endothelium, emigration from the blood stream at sites of inflammation (13, 17–19), degranulation, and release of lysosomal enzymes (20–22) as well as generation of oxygen radicals (22, 23).

There is evidence that leukotrienes, in particular LTD4, enhance leukocyte adhesion to the endothelium by a mechanism dependent on the expression of the CD11/CD18 (Mac-1) glycoprotein family (24) on the leukocyte surface (25, 26). Monoclonal antibodies, which bind to the CD18 glycoprotein portion of the leukocyte adhesion receptors, were reported to inhibit LTD4-induced chemotaxis, adhesion of leukocytes to the endothelium, and macromolecular leakage (11, 26–28) and thus alleviate ischemia-reperfusion injury (29, 30).

The concept that leukotrienes are involved in ischemia-reperfusion injury has furthermore been supported by reports of enhanced generation of 5-lipoxygenase products in postischemic organs (31–34). The recent demonstration of enhanced leukotriene levels in venous effluent from hindlimbs after experimental ischemia and reperfusion (35) suggests that similar mechanisms exist in striated skeletal muscle.

It was the aim of this study to investigate the mediator role of leukotrienes in the pathogenesis of ischemia-reperfusion injury in striated muscle. Using the dorsal skinfold chamber model in hamsters (36) for intravital microscopy of the microcirculation of striated muscle, we demonstrate in this report that leukotrienes elicit the same pattern of microcirculatory changes as ischemia-reperfusion injury and that the posts ischemic microcirculatory failure can be effectively prevented by the inhibition of leukotriene generation or leukotriene receptors, suggesting the key role of leukotrienes in ischemia-reperfusion injury in the striated muscle in vivo.

Methods

Animal model. For intravital fluorescence microscopy, we used the dorsal skinfold chamber preparation in awake Syrian golden hamsters (36). This model permits the microscopic quantification of leukocyte/lymphocyte adhesion to the microvascular surface.

Address correspondence and reprint requests to Dr. Hans-Anton Lehr, Institute for Surgical Research, University of Munich, Marchioninistrasse 15, D-8000 Munich 70, Germany.

Received for publication 28 September 1990 and in revised form 19 December 1990.

© The American Society for Clinical Investigation, Inc.
0021-9738/91/06/2036/06 $2.00
Volume 87, June 1991, 2036–2041

1. Abbreviations used in this paper: LT, leukotriene.
endothelium interaction, macromolecular leakage, and the microcirculatory parameters vessel diameter and red cell velocity in postcapillary venules of a thin striped muscle contained within the observation window.

Operative technique. The experimental preparation used in this study is similar, except for minor modifications, to that described previously in detail (36). Briefly, Syrian golden hamsters (6-8 wk old, weighing 61-80 g) were anesthetized by intraperitoneal injection of pentobarbital (60 mg/kg body weight; Nembutal, Abbott, Wiesbaden, Germany). The entire back of the animals was shaved and two titanium frames were implanted so as to sandwich the extended double layer of the skin. One layer was completely removed in a circular area of 15 mm in diameter and the remaining layer, consisting of epidermis, subcutaneous tissue, and a thin striped skin muscle was covered with a cover slip incorporated in one of the frames. Fine polyethylene catheters (PE) 10, inner diameter 0.28 mm) were inserted into the jugular vein and the carotid artery, respectively, passed subcutaneously to the dorsal side of the neck, and sutured to the titanium frames. The animals tolerated the dorsal skinfold chambers well and showed no signs of discomfort. In particular, no effect on sleeping and feeding habits were observed.

Intravital fluorescence microscopy. A recovery period of 48-72 h between implantation of the observation chamber and the microscopic investigation was allowed to eliminate the effects of anesthesia and surgical trauma on the microcirculation. A 4-h ischemia was induced to the chamber tissue by gently pressing the muscle against the cover slip with a silicone pad and an adjustable screw, just sufficient to empty the blood vessels (6). A 25-fold water immersion objective (total magnification 560-fold; E. Leitz, Inc., Wetzlar, Germany) was used to select four to six sites of interest per chamber, each containing one or several postcapillary venules or collecting venules (10-60 μm in diameter). These vessel segments were chosen for investigation, because they are considered the major site of interaction between leukocytes and the endothelium in response to noxious stimuli (37). By means of a computer-controlled stepping motor (38) the identical vessel segments were investigated for leukocyte/endothelium interaction, diameter, and red cell velocity before ischemia and at all times after reperfusion. For visualization of leukocytes, the in vivo fluorescent marker acridine orange (Sigma Chemical Co., St. Louis, MO) was infused intravenously at a constant rate of 0.5 mg kg⁻¹ min⁻¹ for a maximum microscopic recording of 4-6 min. Epilumination was achieved with a 75 W, DC, xenon lamp attached to a Ploemopak illuminator (E. Leitz, Inc.) with a 15 μm filter block. The microscopic images (Cambridge Instruments, England) were captured on a computer-assisted Microcirculation Analysis System (CAMS) (38). Adhesive leukocytes were defined as cells that did not move or detach from the endothelial lining within the observation time of 1 min and are given as number of cells per mm² of endothelial surface as calculated from diameter and length of the vessel segment studied (200 μm). Macromolecular leakage was assessed by intravenous injection of FITC-conjugated dextran (M, 150,000, 5 μg in 100 μl saline; Pharmacia Fine Chemicals, Uppsala, Sweden), intravital microscopy (total magnification 40-fold), and planimetric quantification of the area where the fluorescent marker had extravasated into the interstitial space, given as a percentage of the observation field (38).

Topical leukotriene application. In order to assess the direct microcirculatory effects of topical leukotriene administration, the leukotrienes LTB₄, LTD₄, (Amersham Bucher, Braunschweig, Germany), and the vehicle (1% ethanol in 0.9% saline) were superfused for a period of 3 min directly onto the striped muscle within the observation window at a concentration of 20 and 5 nM, respectively. The superfusates were then washed away with physiological saline and leukocyte/endothelium interaction, vessel diameters, and red cell velocities were assessed in the follow-up period of 20 min by intravital fluorescence microscopy.

Inhibition of leukotriene synthesis and action. The selective inhibitor of 5-lipoxygenase activation MK-886 (3-[1-(4-chlorobenzyl)-3,5- butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid) (39) was administered intravenously as a bolus of 20 μmol/kg 15 min before induction of ischemia and continued until 2 h after reperfusion at a constant infusion rate of 20 μmol kg⁻¹ h⁻¹. Control animals received equal volumes of vehicle: 1% hamster albumin (Sigma Chemical Co.) and 0.9% benzyl alcohol in 0.9% saline, pH 7.5.

The selective LTD₂/E₄ receptor antagonist MK-571 (3-(3,4-dicarbethoxy-2-chloro-2-quinolinyl)ethenyl)phenyl) (3-(dimethylamino-3-oxopropyl)thiophenyl)-2-thiopropionic acid) (40) was administered intravenously as a bolus of 2 μmol/kg 15 min before induction of ischemia and continued until 2 h after reperfusion at a constant infusion rate of 20 μmol kg⁻¹ h⁻¹. Control animals received equal volumes of vehicle (0.9% saline).

Leukotriene analysis. The tissue content of LTB₄ and of cysteinyl leukotrienes in nonischemic control and ischemic tissue 0.5 h after reperfusion was analyzed by the combined use of RP-HPLC and RIA (41-43). Measurements were performed on animals treated with MK-886 or equivalent volumes of vehicle. Samples were taken from anesthetized hamsters by freezing of the tissue contained within the postschemic observation window in liquid nitrogen. Reference samples were taken from nonischemic tissue next to the observation chamber in the same animal. The tissue was homogenized at 4°C in 80% (vol/vol) aqueous methanol containing 1 mM 4-hydroxy-2,2,6,6-tetramethylpiperidine-N(1)-oxyl (HTMP; Sigma Chemical Co.) and 0.5 mM EDTA, pH 7.4, spiked with 800 cpm each of [³H]LTB₄, [³H]LTC₄, [³H]LTD₄ and [³H]LTE₄ (New England Nuclear, Boston, MA) to correct for recovery losses in the analysis of endogenous leukotrienes, and stored for at least 3 h at 20°C under argon. After centrifugation (10,000 g, 10 min, 4°C), aliquots of the supernatants were dried under vacuum (SpeedVac concentrator; Savant Instruments Inc., HICKsville, NY) and resuspended in 30% (vol/vol) aqueous methanol. Reversed-phase HPNL was performed isocratically on a C₁₈-Hypersil column (4.6 x 250 mm, 5 μm particles; Shandon, Runcorn, England) with a C₁₈ precolumn (Waters Associates, Milford, MA). The mobile phase consisted of 38% (vol/vol) acetonitrile in aqueous buffer (0.1% acetic acid, pH 5.7, adjusted with ammonium hydroxide). The flow rate was 1 ml per min. A 400-μl aliquot of each 1-ml fraction collected during HPLC was counted for calculation of tritium recovery, and 600 μl were dried for the subsequent RIA. The amount of immunoreactive leukotriene metabolites coeluting with the [³H]leukotriene standards added to each sample before HPLC were corrected for recovery losses and immunochemical cross-reactivity in the RIA. The LTB₄ RIA was performed according to the procedure provided by Amersham Bucher. Instead of the charcoal separation system a scintillation proximity assay (protein A) was used. The molar cross-reactivities of the LTB₄ antibody at 50% binding were: LTB₄, 100%; 20-OH-LTB₄, 0.4%; 6-trans-LTB₄, 0.4%; other eicosanoids, < 0.05%. The RIA for cysteinyl leukotrienes was performed as previously described (43).

Statistical analysis. The Wilcoxon test with Bonferroni correction was used for calculating P values. P values of < 0.05 and < 0.01 were considered significant and are denoted in the figures with one or two asterisks, respectively. Data are given in the figures as mean±SD and in the table as mean±SEM.

Results

Microcirculatory changes after ischemia and reperfusion. While under normal conditions, represented by the preischemic baseline situation, the majority of leukocytes passing postcapillary venules and collecting venules did not interact with the endothelial surface, ischemia-reperfusion elicited leukocyte adhesion to the microvascular endothelium with a maximum 0.5 h after reperfusion (Figs. 1 and 2A). This phenomenon was seen in all venules ranging from diameters of 10 to 60 μm. Postschemic leukocyte/endothelium interaction then gradually declined until 24 h after reperfusion (Fig. 2A). Likewise,
macromolecular leakage from postcapillary venules was observed at 0.5 and 2 h after reperfusion (Fig. 3 A). No 24-h values could be obtained for macromolecular leakage because of the highly fluorescent background from preceding investigations.

**Postischemic leukotriene accumulation.** We analyzed the content of 5-lipoxygenase products in the postischemic striated muscle within the observation window after deep-freezing by sequential RP-HPLC and RIA (41–43). The contents of LTB₄ and cysteinyl leukotrienes were significantly increased in postischemic tissues 0.5 h after reperfusion as compared with nonischemic control tissue (Table I).

**Topical leukotriene application.** To test whether topical leukotriene application provoked similar changes in the microcirculation as ischemia-reperfusion, LTB₄ and LTD₄ were superfused directly onto the striated muscle within the observation window. LTB₄ superfusion resulted in an immediate induction of leukocyte adhesion to the endothelium of postcapillary venules and collecting venules, with a maximum at 10 min after superfusion (Fig. 2 B). LTD₄ superfusion caused pronounced macromolecular leakage from these microvascular segments (Fig. 3 B), the time course of this effect being similar as the induction of leukocyte adhesion after LTB₄ challenge. Changes of red blood cell velocity and vessel diameter were not observed after leukotriene application. Superfusion with the vehicle had no effect on leukocyte/endothelium interaction, macromolecular leakage, or microhemodynamic parameters, suggesting that neither the vehicle nor the experimental condition imposed any artefacts on these assessments.

**Inhibition of leukotriene biosynthesis.** In order to demonstrate the essential role of leukotrienes in ischemia-reperfusion injury of striated muscle, leukotriene biosynthesis was pharmacologically inhibited by MK-886, which selectively blocks 5-lipoxygenase activation in vitro (39) and in vivo (39, 43). Effective plasma levels of MK-886 were ascertained at various times by the measurement of LTB₄ generation in whole blood after ex vivo stimulation with the calcium ionophore A23187 according to Tateson et al. (44). The applied dose of MK-886 did not induce changes in blood pressure and heart rate. After 4 h of ischemia and 0.5 h of reperfusion, the accumulation of LTB₄, LTD₄, LTC₄, and LTE₄ in the postischemic chamber tissue was almost completely suppressed in MK-886-treated animals (Table I). Concomitantly, postischemic leukocyte/endothelium interaction and macromolecular leakage from postischemic leukotriene accumulation were observed at 0.5 and 2 h after reperfusion (Fig. 3 A).
Leukotrienes in Ischemia-Reperfusion Injury

Table I. Tissue Content of LTB₄ and Cysteinyl Leukotrienes in Nonischemic Control Tissue and in the Postischemic Chamber Tissue 0.5 h after Reperfusion

<table>
<thead>
<tr>
<th></th>
<th>Control (Vehicle)</th>
<th>MK-886 (0.5 h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LTB₄</td>
<td>13.1±2.9 pmol/g tissue</td>
<td>14.9±4.2 pmol/g tissue</td>
</tr>
<tr>
<td>LTC₄</td>
<td>0.3±0.2</td>
<td>1.0±0.5</td>
</tr>
<tr>
<td>LTD₄</td>
<td>0.3±0.2</td>
<td>1.1±0.8</td>
</tr>
<tr>
<td>LTE₄</td>
<td>0.4±0.2</td>
<td>2.1±1.2</td>
</tr>
<tr>
<td>ΣLTcys</td>
<td>1.1±0.5</td>
<td>4.2±2.5</td>
</tr>
</tbody>
</table>

Reperfusion injury is further supported by the demonstration that leukotrienes accumulate in the postischemic striated muscle 0.5 h after reperfusion (Table I). This finding is in accordance with, and extends, previous reports on increased leukotriene generation in postischemic brain (31), intestine (34), and myocardium (32), as well as elevated leukotriene levels in venous effluent after temporal renal (33) and hindlimb ischemia (35).

When endogenous leukotriene biosynthesis was pharmacologically inhibited by pretreating the animals with the leukotriene biosynthesis inhibitor MK-886, both postischemic leukotriene accumulation and the microcirculatory changes of ischemia-reperfusion injury were entirely prevented (Figs. 2 A and 3 A). This finding extends previous observations obtained in the same animal model, where postischemic capillary blockade was effectively prevented by pretreatment of the animals with the same leukotriene biosynthesis inhibitor (45), and supports the idea that enhanced leukocyte adhesivity accounts for capillary obstruction after ischemia-reperfusion (7). The concept that LT₄ accounts for postischemic leukocyte/endothelium interaction, while the cysteinyl leukotrienes mediate macromolecular leakage, is furthermore substantiated by the finding that postischemic macromolecular leakage was effectively prevented by pretreating the animals with the LTD₄ receptor antagonist MK-571 (Fig. 3 A). These results emphasize the pivotal role of cysteinyl leukotrienes in the regulation of postischemic vessel permeability (13, 14).

MK-886 inhibits leukotriene biosynthesis by blocking the Ca²⁺-dependent translocation of cytosolic 5-lipoxygenase to its membrane-bound activator protein (46-48). In contrast to previously available lipoxygenase inhibitors, which inhibit various lipoxygenases via redox mechanisms (3, 32-34, 49), MK-886 specifically inhibits the synthesis of 5-lipoxygenase products and exerts nonselective antioxidant effects (39). This fact is of particular relevance because oxygen radicals contribute to ischemia-reperfusion injury (8, 10, 11) and since radical scavengers have been reported to alleviate ischemia-induced leukocyte accumulation (3, 9-11) and macromolecular leakage (2, 50). Using nonselective lipoxygenase inhibitors and antioxidants, it could not be decided whether the lipoxygenase inhibitors interfered with oxygen radical formation or, in turn, whether antioxidants interfered with leukotriene generation. Therefore, it was not possible to differentiate the effects of leukotrienes from the effects of oxygen radicals on the microcircu-


25. Toennesen, M. G., D. C. Anderson, T. A. Springer, A. Knepler, N. Avdi,

**Acknowledgments**

The excellent technical assistance of Julian Müller is gratefully acknowledged. MK-886 and MK-571 were kindly provided by Dr. A. W. Ford-Hutchinson, Merck Frosto, Canada.

This study was supported in part by the Deutsche Forschungsgemeinschaft through Sonderforschungsbereich 320 and by the Forschungs schwerpunkt Transplantation, Heidelberg.


